Views & Analysis The first decade of biosimilars – and beyond Sandoz’s CEO Richard Francis on the latest developments in biosimilars.
News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
Views & Analysis Exclusive: Frontiers Health – Day two coverage Frontiers Health is a two-day event focused on disruptive health; innovative technology, application of digital and new ideas which can, are and will transform the face
News Sandoz mhealth hack to address healthcare access Sandoz HACk is encouraging 18-35 year olds to “re-imagine” healthcare.
News Sandoz's Enbrel biosimilar approved in US FDA approves first near-copy of inflammatory diseases drug.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.